Our lead program candidate, STAR-0215, is a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, safe, and effective attack prevention for HAE, with potential for dosing once every 3 and 6 months.
Positive results from our Phase 1a clinical trial in healthy subjects support early proof of concept for STAR-0215’s potential target profile: a long-acting preventative therapy, best-in-class PK profile, and dosing once every 3 and 6 months.
The ALPHA-STAR trial in people living with HAE is on track, enrolling and administering STAR-0215 to patients. Initial proof-of-concept results in HAE patients from single and multiple dose cohorts are expected in Q1 2024.
STAR-0310, a monoclonal antibody OX40 antagonist, is in preclinical development for the potential treatment of atopic dermatitis (AD). STAR-0310 has a potential best-in-class profile: high affinity for competitive efficacy, potential for best-in-class safety and tolerability with low T cell depletion from ADCC or possible on-target cellular toxicity, and less frequent dosing.
We plan to submit an IND for STAR-0310 at the end of 2024 and initiate a Phase 1a trial in the first quarter of 2025, with early proof-of-concept results expected in the third quarter of 2025. Further, we anticipate proof-of-concept results in atopic dermatitis patients in the second quarter of 2026.
At Astria, we are focused on developing differentiated therapeutics for allergic and immunological diseases. Our pipeline represents our vision to improve patients’ quality of life by creating first-choice treatments based on established mechanisms designed to reduce disease and treatment burden.